Last reviewed · How we verify
SPC 2004
At a glance
| Generic name | SPC 2004 |
|---|---|
| Sponsor | Shin Poong Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Peer-led Psycho-education for Schizophrenia (NA)
- Efficacy and Safety of SPC1001 in Patients With Essential Hypertension (PHASE2)
- Smoking Relapse-Prevention Intervention for Cancer Patients (NA)
- WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPC 2004 CI brief — competitive landscape report
- SPC 2004 updates RSS · CI watch RSS
- Shin Poong Pharmaceutical Co. Ltd. portfolio CI